Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MB-GLP1-101
- Development stage
- Preclinical
- Lead developer
- Mercury Bio
- Modality
- Peptides
- Administration
- Oral
01
Overview
MB-GLP1-101 is an investigational oral therapeutic candidate being developed by Mercury Holdings (Mercury Bio) for the treatment of obesity and metabolic disorders. The drug targets the glucagon-like peptide 1 (GLP-1) receptor, a key regulator of appetite and glycemic control. While specific structural details have not been disclosed, the candidate is part of Mercury Bio's pipeline which leverages a proprietary delivery platform using yeast-derived extracellular vesicles (yEVs) to enable the oral administration of biologics that typically require injection. MB-GLP1-101 is currently in the discovery stage, aimed at providing a non-invasive weight loss solution.
02
Targets
Beyond the preview
Go deeper on MB-GLP1-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MB-GLP1-101.